Exploring the effect of researcher choices on statistical results: 73 teams estimate the same effect size with the same data, and generate 1,253 different results. As always, statistical results depend on modeling decisions. pnas.org/doi/10.1073/pn…

For my radiotherapy friends: Ionising radiation and cardiovascular disease: systematic review and meta-analysis bmj.com/content/380/bm…

Pertinent issue across the oncology space! Requirements for Meaningful Progress in the Therapy of Neuroendocrine Cancers ja.ma/3ljrZ1q via JAMA Oncology part of JAMA Network

🚨new job alert🚨 looking for a #postdoc with interests in quants to model choices with our team at Health Economics Research Centre (HERC) further details/apply at tinyurl.com/bdwxr5cb #HealthEconomics

There’s a lot of discussion as to how to manage the cancer backlogs. In this paper we present a model for regional allocation to use all available capacity in the NHS. Can be used across cancer types thelancet.com/journals/lanep…

The (many) problems with a new study criticizing cancer screening Ty ⁦STAT⁩ for providing me space to explain why the question the authors asked is important and why their answer is unsupportable, and likely incorrect. statnews.com/2023/09/07/can…

1/5 Great to see a the first published analysis of the NHS Galleri Trial at the ESMO conference last week in Madrid and the role of NHS DigiTrials in recruiting across a range of ages, socioeconomic and ethnic groups. Success in some areas yet more to do in others.

If you have #systematicreview skills and experience in #healtheconomics #cancer or #datascience we @AUHE_Leeds have an exciting new Cancer Research UK Policy funded post: jobs.leeds.ac.uk/Vacancy.aspx?i… Get in touch with me or Judy Wright for more details!

Fascinating - the hospital at which a patient with Hodgkin lymphoma is treated in England has more effect on the variation in radiotherapy usage than sex of the patient. Suggests standardisation of approach is not yet achieved! #ISHL13 #lymsm. David Cutter David Jones

Out this week, this new publication explores how the distribution of trial site locations, may lead to disparities in patient representation in clinical trials. bit.ly/416VENC David Cutter LymphomaAction Blood Cancer UK National Cancer Audit Collaborating Centre Wiley NHS England Healthcare Quality Improvement Partnership